In a recent interactive webinar, renowned experts Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy and Assoc. Prof. Joshua Richter discussed the challenges of optimising treatment for early relapsed/refractory multiple myeloma (RRMM), exploring current treatment options and sharing insights from clinical practice.

 

Watch the on-demand video to hear the medical experts discuss:

  • Current treatments for early RRMM: Linking mechanism of action to efficacy 
  • Best practices in combining and sequencing therapies for optimal outcomes in early RRMM 
  • Insights from clinical practice on how to manage tolerability and safety 

 

The event concluded with speakers and participants engaging in patient case study discussion and Q&A to address pressing questions. 

 

Not got time to watch the full video? Go to the video highlights: Highlights- Optimising the management of multiple myeloma in the early relapsed refractory setting.

 

Clinical takeaways

  • Myeloma is a continually evolving field with modern day induction regimens yielding near 100% response rates in the front-line setting with typically durable remissions
  • This has been achieved through triplets and quadruplets comprised of the 3 classic MOAs:  IMiD, PI, mAb
  • In the relapsed/refractory space it is important to embrace novel MOAs/targets to optimally manage recurrent disease: XPO1, BCMA, GPRC5d
  • T-cell health is an important long-term consideration for patients to maximise efficacy of T-cell redirection therapy
  • Treatments that are T-cell-sparing, such as XPO1 inhibitors and IMiDs, have the potential to preserve T-cell health

Educational objectives

To educate learners on how to incorporate the latest scientific and clinical insights on the treatment of early RRMM into clinical practice:

  • Knowing the MoA of novel therapies and how this translates into efficacy
  • Learning from best practices on treatment sequencing, treatment combinations and dosing
  • Knowing the safety profiles of novel drugs and understanding the best strategies to manage side effects

Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK. He is an executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his translational research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 50 papers and authored textbooks/ chapters on myeloma

Assoc. Prof. Karthik Ramasamy has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Adaptive, BMS, Biotech, GSK, Janssen, Karyopharm, Oncopeptides, Pfizer and Takeda. 

Joshua Richter, M.D., is an Associate Professor in the Myeloma Division at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai and the Director of Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai.  He completed undergraduate work at Johns Hopkins University and subsequently went on to medical school at New York Medical College. He completed residency at St. Vincent’s Hospital – New York Medical College.  Dr Richter completed his hematology/oncology fellowship at the Yale Cancer Center.  After completing fellowship he worked in the myeloma division at the John Theurer Cancer Center at Hackensack University Medical.  In 2018 he joined the Myeloma Division at Mount Sinai Hospital.   Dr Richter has been published in numerous oncology journals including NEJM, Blood, and the Journal of Clinical Oncology.   He has an interest in immunotherapy, multi-functional antibodies and precision medicine.

Assoc. Prof. Joshua Richter has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Adaptive Biotechnologies, AstraZeneca, BMS, Celgene, Janssen, Karyopharm, Oncopeptides, Secura Bio, Sanofi and X4 Pharmaceuticals. 

Programme summary
Take the e-learning now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LYMPHOMA & MYELOMA CONNECT

LYMPHOMA & MYELOMA CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Bayer, Karyopharm Therapeutics and Menarini Stemline Oncology.

Meet the experts

Other programmes of interest

Video
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Experts
Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Conference update

Episode

1

of 4

episode
Oncology 
ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Experts
Prof. Mark Socinski
  • clock 4 MIN
  • calendar Jun 2024